SGMT
USDSagimet Biosciences Inc. Series A Common Stock
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$7.530
고가
$7.670
저가
$7.020
거래량
0.13M
기업 기본 정보
시가총액
244.6M
산업
생명공학
국가
United States
거래 통계
평균 거래량
0.57M
거래소
NGM
통화
USD
52주 범위
관련 뉴스
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announced completion of
Clear Street Initiates Coverage On Sagimet Biosciences with Buy Rating, Announces Price Target of $29
Clear Street analyst Kaveri Pohlman initiates coverage on Sagimet Biosciences with a Buy rating and announces Price Target of $29.
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic
관련 주식
최신 정보 받기
가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기